Name: AT7867
Price: 280.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA (IC50=32 nM/17 nM/47 nM and 85 nM/20 nM, respectively).
    Akt, also known as protein kinase B, is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription and cell migration.
    AT7867 inhibited cell proliferation in multiple human cancer cell lines, it is most potent in inhibiting MES-SA uterine/MDA-MB-468/MCF-7 breast/HCT116/HT29 colon lines (IC50, 0.9–3 μM). AT7867 also inhibited GSK3β among each cell lines tested (IC50=2-4 μM). In U87MG human glioblastoma cells, AT7867 suppressed AKT signaling and induced apoptosis in a time and concentration-dependent manner. [1]
    In athymic mice implanted with the PTEN-deficient U87MG human glioblastoma xenograft model, AT7867 treatment showed inhibition in phosphorylation of AKT/p70S6K downstream substrates and led to apoptosis. In PTEN-dificient xenograft models, AT7867 inhibited human tumor growth. [1]
- Properties
  - Alternative Name
    
    4-(4-chlorophenyl)-4-[4-(1H-pyrazol-4-yl)phenyl]piperidine
    
    CAS Number
    
    857531-00-1
    
    Molecular Formula
    
    C20H20ClN3
    
    Molecular Weight
    
    337.85
    
    Appearance
    
    A solid
    
    Purity
    
    98.76%
    
    Solubility
    
    ≥16.9 mg/mL in DMSO; ≥4.38 mg/mL in EtOH with ultrasonic; ≥45 mg/mL in H2O
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

AT7867

AT7867

Background

We Also Recommend

BMS-777607

BS-181 HCl

PD318088